NZ598384A - Modulators of toll-like receptors - Google Patents
Modulators of toll-like receptorsInfo
- Publication number
- NZ598384A NZ598384A NZ598384A NZ59838410A NZ598384A NZ 598384 A NZ598384 A NZ 598384A NZ 598384 A NZ598384 A NZ 598384A NZ 59838410 A NZ59838410 A NZ 59838410A NZ 598384 A NZ598384 A NZ 598384A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compounds
- carcinoma
- administration
- toll
- modulators
- Prior art date
Links
- 102000002689 Toll-like receptor Human genes 0.000 title abstract 3
- 108020000411 Toll-like receptor Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- XJBUUVXPCSJTDR-UHFFFAOYSA-N 1,4-dihydropyrido[3,4-b]pyrazine-2,3-dione Chemical compound C1=NC=C2NC(=O)C(=O)NC2=C1 XJBUUVXPCSJTDR-UHFFFAOYSA-N 0.000 abstract 1
- ITAXKXSOVXIGCP-UHFFFAOYSA-N 3,4-dihydro-1h-pyrido[3,4-b]pyrazin-2-one Chemical compound N1=CC=C2NC(=O)CNC2=C1 ITAXKXSOVXIGCP-UHFFFAOYSA-N 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24219409P | 2009-09-14 | 2009-09-14 | |
| PCT/US2010/048424 WO2011031965A1 (en) | 2009-09-14 | 2010-09-10 | Modulators of toll-like receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598384A true NZ598384A (en) | 2014-04-30 |
Family
ID=43332257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598384A NZ598384A (en) | 2009-09-14 | 2010-09-10 | Modulators of toll-like receptors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8476270B2 (enExample) |
| EP (1) | EP2477987B1 (enExample) |
| JP (1) | JP5763077B2 (enExample) |
| AU (1) | AU2010292102B2 (enExample) |
| CA (1) | CA2772253C (enExample) |
| ES (1) | ES2661850T3 (enExample) |
| NO (1) | NO2477987T3 (enExample) |
| NZ (1) | NZ598384A (enExample) |
| PL (1) | PL2477987T3 (enExample) |
| PT (1) | PT2477987T (enExample) |
| SI (1) | SI2477987T1 (enExample) |
| WO (1) | WO2011031965A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
| WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| CN107074860B (zh) * | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
| WO2016106050A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| KR20190084991A (ko) | 2016-11-28 | 2019-07-17 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피라졸로-헤테로아릴 유도체, 이의 제조 방법 및 의학적 용도 |
| WO2018137614A1 (zh) * | 2017-01-24 | 2018-08-02 | 江苏恒瑞医药股份有限公司 | 杂芳基并噻二嗪-2,2-二氧化物类衍生物、其制备方法及其在医药上的应用 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP2020520379A (ja) | 2017-05-18 | 2020-07-09 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用 |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| RU2020116571A (ru) | 2017-12-07 | 2021-11-22 | Эмори Юниверсити | N4-гидроксицитидин и производные и связанные с этим противовирусные применения |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2020012651A (es) | 2018-05-25 | 2021-02-02 | Jiangsu Hengrui Medicine Co | Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion. |
| CN112105620B (zh) * | 2018-05-25 | 2026-02-24 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| KR102514860B1 (ko) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US263470A (en) * | 1882-08-29 | Grate for boiler-furnaces | ||
| US29885A (en) * | 1860-09-04 | Improvement in harrows | ||
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| WO1990014837A1 (en) * | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JP2886570B2 (ja) | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| TW274550B (enExample) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| IL112235A (en) * | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| DK0920429T3 (da) | 1996-08-06 | 2003-05-12 | Pfizer | Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater |
| US5693641A (en) * | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| WO2000000478A1 (en) | 1998-06-26 | 2000-01-06 | Bristol-Myers Squibb Pharma Company | Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
| JP2003509425A (ja) | 1999-09-15 | 2003-03-11 | ワーナー−ランバート・カンパニー | キナーゼ阻害剤としてのプテリジノン |
| US6452325B1 (en) * | 2000-07-24 | 2002-09-17 | Thermoplastic Processes, Inc. | Shatterproofing of fluorescent lamps |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| UY27427A1 (es) | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
| DE50307267D1 (de) | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| EP2269638A3 (en) | 2004-05-28 | 2012-06-13 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| EA200702235A1 (ru) | 2005-05-04 | 2008-04-28 | Пфайзер Лимитед | Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с |
| WO2007014838A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| AU2007216247A1 (en) * | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
| WO2007108968A2 (en) | 2006-03-13 | 2007-09-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| CN101479269A (zh) | 2006-06-23 | 2009-07-08 | 阿斯利康(瑞典)有限公司 | 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途 |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| JP2010519186A (ja) | 2007-02-19 | 2010-06-03 | スミスクライン ビーチャム コーポレーション | 免疫調節物質としてのプリン誘導体 |
| CN101636399B (zh) | 2007-03-22 | 2012-04-18 | 武田药品工业株式会社 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
| BRPI0811125A2 (pt) * | 2007-05-08 | 2017-05-09 | Astrazeneca Ab | imidazoquinolinas com propriedades imunomoduladoras |
| EP2170888B1 (en) * | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| ATE501136T1 (de) * | 2007-08-03 | 2011-03-15 | Pfizer Ltd | Imidazopyridinone |
| AU2008287339A1 (en) | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| WO2009022185A2 (en) | 2007-08-16 | 2009-02-19 | Astrazeneca Ab | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
| WO2009067547A1 (en) | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| UY32306A (es) * | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
-
2010
- 2010-09-10 WO PCT/US2010/048424 patent/WO2011031965A1/en not_active Ceased
- 2010-09-10 AU AU2010292102A patent/AU2010292102B2/en active Active
- 2010-09-10 CA CA2772253A patent/CA2772253C/en active Active
- 2010-09-10 NZ NZ598384A patent/NZ598384A/en not_active IP Right Cessation
- 2010-09-10 ES ES10760831.7T patent/ES2661850T3/es active Active
- 2010-09-10 US US12/879,697 patent/US8476270B2/en active Active
- 2010-09-10 SI SI201031640T patent/SI2477987T1/en unknown
- 2010-09-10 NO NO10760831A patent/NO2477987T3/no unknown
- 2010-09-10 EP EP10760831.7A patent/EP2477987B1/en active Active
- 2010-09-10 PL PL10760831T patent/PL2477987T3/pl unknown
- 2010-09-10 PT PT107608317T patent/PT2477987T/pt unknown
- 2010-09-10 JP JP2012528926A patent/JP5763077B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NO2477987T3 (enExample) | 2018-06-09 |
| EP2477987A1 (en) | 2012-07-25 |
| CA2772253C (en) | 2018-02-27 |
| JP5763077B2 (ja) | 2015-08-12 |
| EP2477987B1 (en) | 2018-01-10 |
| AU2010292102A1 (en) | 2012-03-15 |
| CA2772253A1 (en) | 2011-03-17 |
| AU2010292102B2 (en) | 2015-04-09 |
| PL2477987T3 (pl) | 2018-06-29 |
| SI2477987T1 (en) | 2018-03-30 |
| WO2011031965A1 (en) | 2011-03-17 |
| US20110124627A1 (en) | 2011-05-26 |
| JP2013504593A (ja) | 2013-02-07 |
| US8476270B2 (en) | 2013-07-02 |
| PT2477987T (pt) | 2018-03-13 |
| ES2661850T3 (es) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598933A (en) | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | |
| UA113956C2 (xx) | Похідні піримідину для лікування вірусних інфекцій | |
| SI2477987T1 (en) | MODULATORS TO TOLL OF LIKE RECEPTORS | |
| ZA201002009B (en) | Imidazo[1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis | |
| WO2011156610A3 (en) | Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus | |
| PL2888241T3 (pl) | 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby | |
| PH12013500742A1 (en) | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors | |
| PH12014500103A1 (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
| WO2012166716A3 (en) | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections | |
| PH12014500137A1 (en) | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions | |
| BR112013026355A2 (pt) | compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico | |
| MX2015008467A (es) | Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana. | |
| NO20092585L (no) | Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner | |
| WO2012142523A3 (en) | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment | |
| MY153617A (en) | Pyridin-4-yl derivatives | |
| PH12013502419A1 (en) | Imidazopyridine compounds | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| IN2014MN01547A (enExample) | ||
| WO2012174312A3 (en) | Benzimidazole derivatives as antiviral agents | |
| WO2011163029A3 (en) | Alkenyl substituted cycloaliphatic compounds as chemical inducers of proximity | |
| WO2011001113A3 (fr) | NOUVEAUX DERIVES DE 1,2,3,4-TETRAHYDRO-PYRIMIDO{1,2-a}PYRIMIDIN-6-ONE,LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE | |
| WO2011042860A3 (en) | New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria | |
| MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
| MX2012000097A (es) | Nuevos derivados de 2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ona, su preparacion y su uso en farmaceutica. | |
| WO2012162580A3 (en) | Anti-viral compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 SEP 2017 BY AJ PARK Effective date: 20140822 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2018 BY COMPUTER PACKAGES INC Effective date: 20170818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY COMPUTER PACKAGES INC Effective date: 20180818 |
|
| LAPS | Patent lapsed |